FINAL (2)-150.png
BackTABLEfinal-2tone_edited.png

© 2020 by Backtable. All rights reserved.

Episode 92

Interventional Oncology in Private Practice (Part 2)

with Dr. Justin Lee and Dr. Christopher Beck

BackTable, LLC (Producer). (2020, October 29). Ep. 92 – Interventional Oncology in Private Practice (Part 2) [Audio podcast]. Retrieved from https://www.backtable.com/podcasts

Interventional Radiologist Justin Lee tells us about his approach to treatment of Hepatocellular Carcinoma (HCC), including how this has changed over his years in private practice. This is part two of a two part series.

Special thanks to our sponsor

Podcast Participants

Dr. Justin Lee

Dr. Justin Lee is a practicing interventional radiologist at Radiology Associates of Florida in Tampa, FL.

Dr. Christopher Beck

Host Dr. Chris Beck is a practicing interventional radiologist with Regional Radiology Group in New Orleans.

TriSalus Infusion Systems

TriSalus Life Sciences is dedicated to improving patient outcomes in HCC and other highly intractable solid tumors. TriSalus Infusion Systems have the potential to deliver diagnostic, therapeutic, and immuno-stimulant agents directly into the tumor vascular, powered by their proprietary pressure-enabled delivery approach.

TriSalus Life Sciences Sponsorship on BackTable

Show Notes

In this episode, Dr. Justin Lee joins Dr. Christopher Beck to discuss hepatocellular carcinoma (HCC) and interventional oncology in private practice. Dr. Lee tells us how he frames his HCC patients and works with medical oncologists for treatment plans and procedures.

We talk about the importance of IR bringing cases to the tumor board, the evolution of cases involving ablation, and why Dr. Lee started moving towards radioembolization (Y90). We review how to approach HCC cases while working with medical oncologists.

We examine the differences between using resin and glass for radioembolization and when they should be used. Dr. Lee shares why IR should start looking into arterial drug delivery for immunotherapies.


RESOURCES MENTIONED:

NEJM: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
https://www.nejm.org/doi/10.1056/NEJMoa1915745
This paper, mentioned by Dr. Lee, discusses the third phase of an HCC trial.

Transcript Preview

This transcript is not yet available.

Join The Discussion

Related Content

No related content.

Podcast

Amplatzer Plugs vs. Coils in Splenic Trauma

Podcast

Interventional Oncology in Private Practice (Part 1)

Demo Video

Go Get It! | J.A. Mustapha | TEDxGrandRapids

Demo Video

Believe in Better Medicine | Dr. Oleksandra Kutsenko | TEDxSyracuse

Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

 
TriSalus Infusion System on BackTable

Submit this form to get in touch with a rep and learn more about treating solid tumors with TriSalus Infusion Systems.

TriSalus Infusion System on BackTable